A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-escalation and Food Effect Study to Assess the Safety, Tolerance, and Pharmacokinetics of FZJ-003 In Healthy Volunteers
Latest Information Update: 14 Mar 2025
At a glance
- Drugs FZJ-003 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions
- Sponsors Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
Most Recent Events
- 12 Mar 2025 Status changed from recruiting to completed.
- 15 Mar 2022 Planned End Date changed from 31 Dec 2021 to 30 Jun 2023.
- 15 Mar 2022 Planned primary completion date changed from 31 Dec 2021 to 31 May 2023.